Related Experiment Video

Updated: Jun 4, 2026

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes
05:08

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes

Published on: August 24, 2018

[Non-enzymatic glycation of proteins: from diabetes to cancer]

N A Ansari, Z Rasheed

    Biomeditsinskaia Khimiia
    |February 24, 2011
    PubMed

    Insights

    Non-enzymatic glycation of proteins forms early and advanced glycation endproducts (AGEs). These products are key biomarkers for diabetes complications and diseases like cancer, offering novel therapeutic targets.

    Area of Science:

    • Biochemistry
    • Endocrinology
    • Pathology

    Background:

    • Non-enzymatic glycation of proteins, or the Maillard reaction, is increased in diabetes due to hyperglycemia.
    • This process leads to the formation of Amadori products (early glycation) and advanced glycation endproducts (AGEs).
    • AGEs are implicated in diabetic complications (blindness, heart disease, nerve damage, kidney failure) and other diseases like cancer.

    Purpose of the Study:

    • To review the current knowledge on stage-specific glycated products.
    • To highlight their role as early diagnostic biomarkers for diseases and complications.
    • To explore their potential as novel therapeutic targets.

    Main Methods:

    • Literature review of studies on protein glycation and its products.
    • Analysis of the formation pathways of early and advanced glycation endproducts.
    • Evaluation of diagnostic and therapeutic implications of glycated products.

    Main Results:

    • Amadori products are early glycation products, and their oxidative cleavage forms AGEs.
    • Accumulation of glycated products in diabetic patients leads to autoantibody production.
    • Both early and advanced glycation products show potential as diagnostic biomarkers.

    Conclusions:

    • Glycated proteins, including Amadori products and AGEs, are significant in diabetes and other diseases.
    • These products serve as valuable early diagnostic biomarkers.
    • Targeting glycation pathways presents a promising therapeutic strategy.

    More Related Videos

    Glycan Node Analysis: A Bottom-up Approach to Glycomics11:36

    Glycan Node Analysis: A Bottom-up Approach to Glycomics

    Published on: May 22, 2016

    Related Concept Videos

    Type II Diabetes II: Pathophysiology01:24

    Type II Diabetes II: Pathophysiology

    PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
    Proteoglycans01:05

    Proteoglycans

    Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
    Diabetic Nephropathy01:28

    Diabetic Nephropathy

    Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
    Type I Diabetes II: Pathophysiology01:26

    Type I Diabetes II: Pathophysiology

    Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
    Diabetic Neuropathy01:22

    Diabetic Neuropathy

    DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
    Hyperglycemia01:29

    Hyperglycemia

    Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...